COVID-19: Boehringer Ingelheim Clinical Trials

- to temporarily stop recruitment of new participants in ongoing clinical trials sponsored by Boehringer Ingelheim
- to ensure supply of medication for clinical trial participants recruited and already on treatment. Continued provision with medication will be arranged for.
- to temporarily hold clinical site initiation.
Clinical investigators and health authorities worldwide, where required, are currently being informed about this development. The situation will be constantly monitored and assessed.
NP-IE-100282 | March 2020